Travere Therapeutics, Inc. (TVTX)
52.12
+0.08
(+0.16%)
USD |
NASDAQ |
Oct 09, 16:00
52.17
+0.04
(+0.09%)
After-Hours: 20:00
Travere Therapeutics Net Income (Quarterly) : -34.80M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -34.80M |
| March 31, 2026 | -36.60M |
| December 31, 2025 | -21.99M |
| September 30, 2025 | 25.71M |
| June 30, 2025 | -12.76M |
| March 31, 2025 | -41.23M |
| December 31, 2024 | -60.27M |
| September 30, 2024 | -54.75M |
| June 30, 2024 | -69.65M |
| March 31, 2024 | -135.96M |
| December 31, 2023 | -88.60M |
| September 30, 2023 | -89.24M |
| June 30, 2023 | -85.63M |
| March 31, 2023 | -96.56M |
| December 31, 2022 | -85.64M |
| September 30, 2022 | -84.06M |
| June 30, 2022 | -67.03M |
| March 31, 2022 | -75.97M |
| December 31, 2021 | -51.57M |
| September 30, 2021 | -35.64M |
| June 30, 2021 | -39.01M |
| March 31, 2021 | -53.87M |
| December 31, 2020 | -121.62M |
| September 30, 2020 | -22.55M |
| June 30, 2020 | -26.07M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.808M |
| December 31, 2019 | -30.26M |
| September 30, 2019 | -36.49M |
| June 30, 2019 | -38.70M |
| March 31, 2019 | -40.98M |
| December 31, 2018 | -7.455M |
| September 30, 2018 | -54.52M |
| June 30, 2018 | -22.33M |
| March 31, 2018 | -18.38M |
| December 31, 2017 | -17.62M |
| September 30, 2017 | -17.79M |
| June 30, 2017 | -13.23M |
| March 31, 2017 | -11.09M |
| December 31, 2016 | -8.603M |
| September 30, 2016 | -37.11M |
| June 30, 2016 | -13.40M |
| March 31, 2016 | 11.22M |
| December 31, 2015 | -2.469M |
| September 30, 2015 | 105.58M |
| June 30, 2015 | -25.53M |
| March 31, 2015 | 39.66M |
| December 31, 2014 | -29.03M |
| September 30, 2014 | -19.56M |
| June 30, 2014 | 8.483M |
| March 31, 2014 | -70.63M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 7.781M |
| BioMarin Pharmaceutical, Inc. | 44.76M |
| Vertex Pharmaceuticals, Inc. | 1.100B |
| Viridian Therapeutics, Inc. | -127.12M |
| Krystal Biotech, Inc. | 54.77M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 169.58M |
| Total Expenses (Quarterly) | 204.38M |
| EPS Diluted (Quarterly) | -0.3722 |
| Enterprise Value | 5.037B |
| Gross Profit Margin (Quarterly) | 96.22% |
| Profit Margin (Quarterly) | -20.52% |
| Earnings Yield | -1.46% |
| Normalized Earnings Yield | -0.8904 |